Common questions about Цикло-Прогинова (FAQ)
Q: Is Цикло-Прогинова the same as other hormone replacement therapies (HRT)?
A: No, Cyclo-Progynova belongs to a specific type of hormone replacement therapy known as sequential combined HRT. This means the estrogen and progestogen components are administered in a planned, sequential pattern throughout the cycle. This differs from continuous regimens, where both hormones are taken simultaneously every day.
Q: Does Цикло-Прогинова help regulate the menstrual cycle?
A: Regulatory documents indicate that this medication is used to manage certain issues related to the menstrual cycle. It is specifically indicated for the treatment of primary and secondary amenorrhea (the absence of menstrual periods) and to help establish a regular cycle when the natural hormonal rhythm is disrupted.
Q: Why are there two different types of tablets (white and light-brown) in the pack?
A: The different tablet colors reflect the different hormone combinations required for the sequential treatment. The white tablets contain only the estrogen component, estradiol valerate. The light-brown tablets contain both the estrogen (estradiol valerate) and the progestogen (norgestrel), which is included to protect the lining of the uterus (endometrium).
Q: What is the difference between sequential HRT (like this drug) and continuous HRT?
A: Sequential combined HRT, which includes Cyclo-Progynova, is structured to mimic the natural menstrual cycle by cycling the hormone components. This regimen typically leads to a predictable, period-like withdrawal bleed each month. Continuous combined HRT provides a steady dose of both hormones daily and is designed for women who wish to avoid regular bleeding.
Q: What specific ingredients are in the white tablets versus the light-brown tablets?
A: The white tablets contain only the active ingredient estradiol valerate. The light-brown tablets contain both estradiol valerate and the progestogen norgestrel. This two-phase structure ensures the uterine lining is protected while providing estrogen replacement.
Q: Why is it called 'cyclic' hormone therapy?
A: The term 'cyclic' refers to the structured, repeating schedule of the medication. The active hormones are administered in a predetermined, alternating pattern over a 28-day cycle, designed to result in a planned withdrawal bleed, similar to a natural menstrual rhythm.
Q: What age range is Цикло-Прогинова typically prescribed for?
A: Official information defines the eligible patient population as adult women. The medicine is used to treat symptoms of estrogen deficiency in women around the time of menopause, and for certain menstrual disorders in younger women. Use in children and adolescents under 18 years is not established.
Q: Can this medication affect the results of blood tests?
A: According to regulatory documents, the use of hormone replacement therapy can affect the results of certain laboratory tests. This may include tests that measure endocrine and hepatic function, as well as tests for various plasma protein levels.
Q: Why might a doctor prescribe Цикло-Прогинова for primary or secondary amenorrhea?
A: The drug is officially indicated for the treatment of primary and secondary amenorrhea, which means it may be used when periods are missing due to the body not producing enough hormones. The therapy helps to initiate and regulate the cycle in these cases.
Q: Is there a regulatory requirement to have regular check-ups while taking this medicine?
A: Yes, a thorough general and gynaecological check-up is required before starting treatment, according to regulatory guidelines. Regulatory precautions recommend regular medical follow-up examinations and that patients be advised on methods for self-examining their breasts.
Q: Does Цикло-Прогинова affect mood or anxiety levels?
A: Official reports on undesirable effects list mood changes and depressive mood as possible reactions associated with this medicine. Individuals who experience significant changes in mood should discuss these concerns with their healthcare provider.
Q: Is Цикло-Прогинова a contraceptive (birth control pill)?
A: No, regulatory information clarifies that this medicine does not inhibit ovulation and is not intended for contraception. If contraception is needed, regulatory information recommends the use of an additional, non-hormonal method.
Q: Is it common to experience changes in vision while using this medication?
A: The official documentation lists certain conditions, including visual disturbances and intolerance to contact lenses, as possible adverse effects associated with this type of hormone therapy.
Q: What if I vomit shortly after taking a tablet of Цикло-Прогинова?
A: The patient information leaflet provides guidelines for a situation where the tablet may not have been absorbed. If vomiting or severe diarrhea occurs within 3 to 4 hours of taking a tablet, the standard instructions for a missed dose should be followed.
Q: Is there a known link between Цикло-Прогинова and hair loss?
A: Regulatory documents include adverse events related to hair. Alopecia (which is a medical term for hair loss) is listed as a possible undesirable effect of the drug.
Q: Does Цикло-Прогинова contain lactose or other common allergens?
A: Yes, the official list of excipients confirms that the tablets contain lactose monohydrate. Official labeling highlights that patients with known intolerances should note this information.
Q: Is it true that official sources advise against smoking while taking this type of medication?
A: Regulatory warnings indicate that smoking is a risk factor that significantly increases the potential for serious vascular side effects. Since this medication is associated with a risk of blood clots, smoking should be carefully considered as it adds to that overall cardiovascular risk profile.
Q: Can using Цикло-Прогинова affect the risk of gallstones?
A: Yes, official safety warnings for this class of hormone replacement therapy note that it is associated with a slightly increased risk of developing gallbladder disease. This is a known risk factor related to the use of combined estrogen and progestogen products.
Q: Does being overweight change eligibility for taking Цикло-Прогинова?
A: Regulatory precautions list obesity as a factor that may increase the risk of certain serious side effects, specifically venous thromboembolism (blood clots). Official documentation notes that this requires careful consideration by a healthcare provider before treatment is initiated.
Q: Is it considered safe to drive or operate machinery while taking Цикло-Прогинова?
A: The regulatory documents include a specific section on this topic. They state that no effects on the ability to drive or use machinery have been observed.
Q: Why do some sources mention a risk of depression with HRT like Цикло-Прогинова?
A: Official regulatory documents list depression as a possible adverse drug reaction for this medication. Any individual experiencing depression during treatment should seek consultation with their healthcare provider.
